Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
Randomized, Multicenter, Double-blind, Double-dummy, Parallel-Group Study With an Open-label Extension Phase to Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
Sponsor: Eisai Co., Ltd.
A PHASE3 clinical study on Alzheimer's Type Dementia, this trial is completed. The trial is conducted by Eisai Co., Ltd. and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Age, Japan , Akita, Japan , Amagasaki, Japan , Anan, Japan , Anjo, Japan , Bunkyo-ku, Japan , Chiba, Japan , Chikushi, Japan , Fuji, Japan , Fukuoka, Japan and 43 more locations